Bumpus Namandje has filed 4 insider transactions across 1 company since March 2025.
Most recent transaction: a grant/award of 11008 shares of RECURSION PHARMACEUTICALS, INC. ($RXRX) on June 18, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Bumpus Namandje | Director | A | Class A Common Stock | 11008 | $0.00 | 47,557.0000 | 395,072,094 | 30.12% | 0.00% |
| June 18, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Bumpus Namandje | Director | A | Stock Option (Right to Buy) | 22016 | $0.00 | 22,016.0000 | 395,072,094 | 9999.99% | 0.01% |
| March 17, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Bumpus Namandje | Director | A | Class A Common Stock | 36549 | $0.00 | 36,549.0000 | 395,072,094 | 9999.99% | 0.01% |
| March 17, 2025 | RECURSION PHARMACEUTICALS, INC. | $RXRX | Bumpus Namandje | Director | A | Stock Option (Right to Buy) | 73099 | $0.00 | 73,099.0000 | 395,072,094 | 9999.99% | 0.02% |